Detorsertib - Suzhou Kintor Pharmaceuticals
Alternative Names: GT-0486Latest Information Update: 20 Jun 2024
Price :
$50 *
At a glance
- Originator Suzhou Kintor Pharmaceuticals
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 28 Aug 2023 Detorsertib is still in phase I trials for Solid tumours China
- 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in China